Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

167 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Microsatellite instability associated with durable complete response to PD-L1 inhibitor in head and neck squamous cell carcinoma.
Tardy MP, Di Mauro I, Ebran N, Refae S, Bozec A, Benezery K, Peyrade F, Guigay J, Sudaka-Bahadoran A, Badoual C, Pedeutour F, Saada-Bouzid E. Tardy MP, et al. Among authors: peyrade f. Oral Oncol. 2018 May;80:104-107. doi: 10.1016/j.oraloncology.2018.04.001. Epub 2018 Apr 7. Oral Oncol. 2018. PMID: 29631799 No abstract available.
Molecular genetics of head and neck squamous cell carcinoma.
Saada-Bouzid E, Peyrade F, Guigay J. Saada-Bouzid E, et al. Among authors: peyrade f. Curr Opin Oncol. 2019 May;31(3):131-137. doi: 10.1097/CCO.0000000000000536. Curr Opin Oncol. 2019. PMID: 30893149 Review.
Approach to the Patient with Recurrent/Metastatic Disease.
Guigay J, Sâada-Bouzid E, Peyrade F, Michel C. Guigay J, et al. Among authors: peyrade f. Curr Treat Options Oncol. 2019 Jun 25;20(8):65. doi: 10.1007/s11864-019-0664-z. Curr Treat Options Oncol. 2019. PMID: 31240480 Review.
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
Guigay J, Aupérin A, Fayette J, Saada-Bouzid E, Lafond C, Taberna M, Geoffrois L, Martin L, Capitain O, Cupissol D, Castanie H, Vansteene D, Schafhausen P, Johnson A, Even C, Sire C, Duplomb S, Evrard C, Delord JP, Laguerre B, Zanetta S, Chevassus-Clément C, Fraslin A, Louat F, Sinigaglia L, Keilholz U, Bourhis J, Mesia R; GORTEC; AIO; TTCC, and UniCancer Head and Neck groups. Guigay J, et al. Lancet Oncol. 2021 Apr;22(4):463-475. doi: 10.1016/S1470-2045(20)30755-5. Epub 2021 Mar 5. Lancet Oncol. 2021. PMID: 33684370 Clinical Trial.
Evaluation of the information given to patients undergoing head and neck cancer surgery using the EORTC QLQ-INFO25 questionnaire: A prospective multicentric study.
Bozec A, Schultz P, Gal J, Chamorey E, Chateau Y, Dassonville O, Poissonnet G, Santini J, Peyrade F, Saada E, Guigay J, Benezery K, Leysalle A, Santini L, Giovanni A, Messaoudi L, Fakhry N. Bozec A, et al. Among authors: peyrade f. Eur J Cancer. 2016 Nov;67:73-82. doi: 10.1016/j.ejca.2016.08.005. Epub 2016 Sep 9. Eur J Cancer. 2016. PMID: 27616438
167 results